Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could years of eye injections weigh down the upper eyelid?

NCT ID NCT07821450

Knowledge-focused Sponsor: Abdulkadir Küçük Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Doctors use anti-VEGF injections to treat retinal diseases such as age-related macular degeneration and diabetic macular edema, and patients often need these shots for years. During each injection, a small tool holds the eyelids open, stretching the upper lid. Researchers want to know whether this repeated stretching changes eyelid position over time. The study follows 60 adults who are starting injections in one eye only, using the untreated eye as a comparison, and measures eyelid height and muscle function at set visits over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If repeated injections do affect eyelid position, doctors could adjust how they hold the eyelid open or counsel patients about this possible side effect.
What could go wrong
This is a small observational study at one center, so any link it finds may not hold up in larger or more varied groups. It cannot prove that injections cause eyelid drooping.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older with a retinal disease (neovascular age-related macular degeneration, diabetic macular edema or retinal vein occlusion) scheduled to begin intravitreal anti-VEGF therapy in one eye only, with no history of intravitreal injection in either eye, recruited consecutively at a single tertiary ophthalmology clinic in Istanbul, Turkey.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Planned initiation of intravitreal anti-VEGF injection in one eye only for a retinal disease * No prior intravitreal injection in either eye * Able to attend the scheduled follow-up visits and to cooperate for the duration of the study * Reliable MRD-1, MRD-2 and levator function measurement possible in both eyes (clear corneal light reflex, clearly visible eyelid margin, able to maintain primary gaze) * Signed informed consent Exclusion Criteria: * Pre-existing blepharoptosis or significant eyelid malposition at the baseline examination * Previous ptosis surgery, blepharoplasty or other eyelid surgery that may affect upper eyelid anatomy * History of myasthenia gravis, oculomotor nerve palsy, Horner syndrome, facial nerve palsy or a similar neurologic or neuromuscular disorder * History of orbital trauma, orbital surgery or orbital disease * Advanced dermatochalasis, eyelid retraction, entropion, ectropion or marked facial asymmetry precluding reliable eyelid measurement * Need for intravitreal injection in both eyes during the study period * Ocular or periocular surgery during follow-up that may affect upper eyelid position * Inability to comply with follow-up visits or incomplete measurements * Withdrawal of consent * Inability to obtain reliable eyelid measurements due to severe blepharospasm, advanced corneal opacity, marked eyelid edema, or inability to maintain head or neck position or to cooperate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration diabetic macular edema macular degeneration ptosis wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration Blepharoptosis Diabetic macular edema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.